about
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateClinical outcomes in psoriatic arthritis: A systematic literature reviewScleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsCurrent evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH.Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making.The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis.Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review.Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.Abatacept therapy and safety management.Impact of co-morbidities on measuring indirect utility by the Medical Outcomes Study Short Form 6D in lower-limb osteoarthritis.Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis.Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis.The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.[The main directions in case of polyarthritis].Osteomyelitis in adults: an underrecognized clinical entity in immunocompetent hosts. A report of six cases.Prevalence of Renal Impairment in Patients With Rheumatoid Arthritis: Results From a Cross-Sectional Multicenter Study.Who are the patients with early arthritis with worse than death scores on the EQ-5D? Results from the ESPOIR cohort.
P50
Q26859134-C1F2CE89-3AF3-4FC6-BDC1-6B0110426DBDQ26995307-B3190895-DACF-4262-9B38-97FBFCEA0396Q34102542-7AE64FD6-F6CF-4340-97CE-DFC922C94508Q34110066-7BB26529-7C99-4511-994C-F4CF43241D8AQ34113970-A588D132-B35E-410A-9E65-B03B5DA7D340Q34457872-7F7F366E-3567-41FA-91E9-A50F8AE81B69Q35084199-300AAD63-C29A-4FD3-81F8-A2B689CF9551Q35654047-2106C64D-F3A6-4010-97E9-3F42B65003F3Q36166791-F30B207E-5B4F-4A38-96FC-94B4B4C4FE62Q36885296-4DF4E5AB-490A-42ED-B6A3-7F4613DE9AB7Q37833377-D5F5A004-ECF0-4707-BC68-19E00BFCCF1CQ37858789-380FEF90-3DB7-4B88-BD3B-CFB879973480Q37890664-D5E8C668-136B-4298-BAD1-CC9E256A4F85Q37908827-370649ED-5BA4-4A52-B749-9126B73296BEQ38006176-B22B0F31-C82C-45B6-B516-C4E21086BD7AQ38065446-5C986B73-9B14-4F1F-9DF4-F0DF4EDDC90DQ38176549-5DBF4F22-1918-45EB-B979-134711E0EFC0Q38176745-AB527035-11D8-4123-A936-3049FA6BE9C7Q38211695-90D65B21-18CB-48C1-A499-317C4318A2ADQ38225477-D11D1CFC-0323-4BAE-8E51-12E3F8AAF911Q39412351-AC8394EF-B619-4643-88D0-2A9AEF445F2CQ40256992-2F91FD65-4443-4995-ADF4-F4FC1E185CA4Q40264926-BEE197C9-4650-4DD7-827F-46C17984CD94Q40350083-F2D0873F-FF9B-4746-A257-82942DF3C427Q41445553-7F4CBFC1-0CDA-4923-B4D5-CA8172D8E357Q45087624-0090551E-B010-4ED4-8E86-720D67E48C86
P50
name
Cécile Gaujoux-Viala
@ast
Cécile Gaujoux-Viala
@en
Cécile Gaujoux-Viala
@nl
type
label
Cécile Gaujoux-Viala
@ast
Cécile Gaujoux-Viala
@en
Cécile Gaujoux-Viala
@nl
prefLabel
Cécile Gaujoux-Viala
@ast
Cécile Gaujoux-Viala
@en
Cécile Gaujoux-Viala
@nl